Evidence from the reviewed cohorts supports an exposure–risk association rather than a tested intervention; it is reasonable to infer that stricter CT justification, organ-dose optimization, and appropriate use of non-ionizing imaging could reduce avoidable radiation-associated malignancies without withholding clinically necessary CT.

The record provides observational evidence that adding icaritin to TACE may improve survival in intermediate-to-advanced HCC with preserved liver function; it remains an inference requiring prospective randomized testing that immunomodulation by icaritin causes this benefit, and no pediatric efficacy or safety conclusion can be drawn.

The trial provides preliminary evidence that yoga may be a useful alternative component of pediatric oncology rehabilitation for improving fine motor integration, agility, and overall motor proficiency; any broader benefit for fatigue, quality of life, motivation, cancer outcomes, or treatment toxicity remains inferential and unproven by this record.

The evidence shows associations of age and sex with survival and prescription-based proxies for immune-related adverse events; it supports the hypothesis, but does not establish, that integrating demographic and clinical factors could improve pembrolizumab treatment selection or toxicity monitoring.

The evidence supports repeated supportive-care-needs scores as a potential dynamic prognostic marker; it is only an inference—not tested here—that screening followed by individualized supportive-care intervention could improve symptoms, treatment tolerance, or survival.

The reported associations support investigating modified SIOPEL-4 as a potentially more effective regimen for high-risk pediatric hepatoblastoma; however, whether the regimen itself causes superior survival or offers a better efficacy-to-toxicity balance remains an inference requiring prospective, risk-adjusted comparison.

The study provides observational evidence that early MRD and marrow-response assessment identifies children at increased risk of poor outcomes; it supports—but does not test—the hypothesis that broader access to these diagnostics and response-adapted treatment intensification could improve risk selection and outcomes in this resource-limited setting.

Evidence summarized in the review supports superior technical and diagnostic visualization with 7-T MRI; it is reasonable but unproven to hypothesize that these capabilities could improve treatment selection, surgical or radiotherapy planning, and response assessment in pediatric neuro-oncology.

The reviewed evidence suggests that integrating cardiac biomarkers with therapy-specific mechanisms and psychological-stress assessment could support earlier detection and personalized mitigation of cancer therapy-induced cardiotoxicity; however, the supplied record does not establish the efficacy, safety, or pediatric benefit of any specific intervention.

The record supports NTRK fusions as active, potentially targetable alterations in some adult sarcomas; it further suggests—but does not establish—that histology, fusion partner, and co-occurring genomic alterations may help distinguish tumors likely to remain dependent on TRK signaling and benefit from TRK inhibition.

The review reports recurrent molecular alterations and identifies CD30-directed therapy, JAK/STAT inhibition, and checkpoint blockade as emerging approaches; it is reasonable to hypothesize that molecularly stratified pediatric patients could benefit from these strategies, but the supplied record provides no pediatric efficacy or safety results establishing that benefit.

The reported associations support the hypothesis that pre-transplant germline testing could help stratify HSCT risk and inform donor selection, especially by avoiding potentially variant-sharing related donors for homozygous carriers; however, this is an inference from retrospective data and does not establish a donor-selection standard.